BioPlus Acquisition Corp. Class A Ordinary Shares
Compare this stock
BIOS Stock Report Card
$
52%
Performance
Score:
100/100
BIOS returned 7.25% in the last 12 months. Based on SPY's performance of -3.02%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
Score:
88/100
6 analysts offer 12-month price targets for BIOS. Together, they have an average target of 0, the most optimistic target put BIOS at 0 within 12-months and the most pessimistic has BIOS at 0. These analyst ratings are from our partners at Financial Modeling Prep (https://site.financialmodelingprep.com/) and Alpha Vantage (https://www.alphavantage.co/).
Profit
Score:
12/100
Out of the last 20 quarters, BIOS has had 4 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
10/100
BIOS has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.
BioPlus Acquisition Corp. Class A Ordinary Shares Summary
Nasdaq / BIOS
Financial Services
Shell Companies
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
BIOS scored highly on our reportcard. Here are some similar companies and how they performed.
